愛爾眼科(300015.SZ):九家旗艦醫院已經基本陸續建成並投入運營,意味着大項目建設階段基本結束
格隆匯9月24日丨愛爾眼科(300015.SZ)在投資者關係活動上表示,“1+8+N”戰略,即:建設1家世界級眼科醫院,即長沙醫院;建設8家國家級區域眼科中心,即北京、上海、廣州、深圳、武漢、瀋陽、成都、重慶醫院;“N”指的是全國其他愛爾眼科醫療機構。龍頭旗艦醫院要具備全國其至全球影響力,省會醫院要做到全省一流,標誌性醫院在醫療技術、服務水平、人才梯隊、學術科研、品牌聲譽等方面起到引領作用,帶動公司整體進一步發展,再上新的台階。目前,這九家旗艦醫院已經基本陸續建成並投入運營,意味着大項目建設階段基本結束,公司進入了“拔高”的新階段,技術提高了、服務提高了、品牌影響力提高了,老醫院的天花板也就提高了。中國人口多,只要做得好,不怕做不大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.